NCT04622774: First-in-Human Study of IMGC936 in Participants With Advanced Solid Tumors

Summary

This study is a Phase 1/2, first-in-human, open-label, dose-escalation, and expansion study designed to characterize the safety, tolerability, pharmacokinetics, immunogenicity, and preliminary antitumor activity of IMGC936 administered by intravenous (IV) infusion.

Timeline

Start: 2020-10-29
Primary completion: 2023-12-28
Completion: 2023-12-28

Publications

Park EJ, Lee CW. Soluble receptors in cancer: mechanisms, clinical significance, and therapeutic strategies. Exp Mol Med. 2024 Feb;56(1):100-109. doi: 10.1038/s12276-023-01150-6. Epub 2024 Jan 5.
Scribner JA, Hicks SW, Sinkevicius KW, Yoder NC, Diedrich G, Brown JG, Lucas J, Fuller ME, Son T, Dastur A, Hooley J, Espelin C, Themeles M, Chen FZ, Li Y, Chiechi M, Lee J, Barat B, Widjaja L, Gorlatov S, Tamura J, Ciccarone V, Ab O, McEachem KA, Koenig S, Westin EH, Moore PA, Chittenden T, Gregory RJ, Bonvini E, Loo D. Preclinical Evaluation of IMGC936, a Next-Generation Maytansinoid-based Antibody-drug Conjugate Targeting ADAM9-expressing Tumors. Mol Cancer Ther. 2022 Jul 5;21(7):1047-1059. doi: 10.1158/1535-7163.MCT-21-0915.

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	IZELTABART TAPATANSINE	Unknown	0.5 mg/kg	Intravenous
Subject	IZELTABART TAPATANSINE	Unknown	1 mg/kg	Intravenous
Subject	IZELTABART TAPATANSINE	Unknown	2 mg/kg	Intravenous
Subject	IZELTABART TAPATANSINE	Unknown	4 mg/kg	Intravenous
Subject	IZELTABART TAPATANSINE	Unknown	5 mg/kg	Intravenous
Subject	IZELTABART TAPATANSINE	Unknown	6 mg/kg	Intravenous
Subject	IZELTABART TAPATANSINE	Unknown	7 mg/kg	Intravenous

Indications

No indication recorded.